See Detailed Description
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009163/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study was designed to test the efficacy, safety, tolerability and durability of the
antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC)
Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by
randomization to either a simplification regimen of ATV or continuation of ATV +/r for an
additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1
infected, HLA-B*5701 negative subjects.
All subjects who complete the 84-week study will be eligible to enter the treatment extension
phase and continue for an additional 60 weeks. The purpose of this extension is to obtain
longer term treatment data in subjects who have completed the 84-week study.
提供机构：
Vivli
创建时间：
2023-08-15
